American Association for Cancer Research
Browse
10780432ccr152620-sup-157534_1_supp_3614612_2bgd2j.pdf (378.75 kB)

Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

Download (378.75 kB)
journal contribution
posted on 2023-03-31, 18:30 authored by Yogesh S. Jethava, Alan Mitchell, Joshua Epstein, Maurizio Zangari, Shmuel Yaccoby, Erming Tian, Sarah Waheed, Rashid Khan, Xenofon Papanikolaou, Monica Grazziutti, Michele Cottler-Fox, Nathan Petty, Douglas Steward, Susan Panozzo, Clyde Bailey, Antje Hoering, John Crowley, Jeffrey Sawyer, Gareth Morgan, Bart Barlogie, Frits van Rhee

Supplementary Figure 1: Consort flow diagram of patient flow through TT4 arms Supplementary Figure 2: Cumulative Incidence of Death and Post-Relapse Survival (P-values for S-TT4 vs L-TT4; TRM, p = 0.61; MRM, p = 0.70; OIM, p = 0.25). Supplementary Figure 3: Clinical outcomes according to the presence of PETidentified focal lesions (FL; =<3 v >3) by TT4 arm Supplementary Figure 4: Ingenuity pathways identified a network of 8 interrelated genes.

Funding

NCI

NIH

History

ARTICLE ABSTRACT

Purpose: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy.Experimental Design: A total of 289 patients with gene expression profiling (GEP70)-defined low-risk multiple myeloma were randomized between a standard arm (TT4-S) and a light arm (TT4-L). TT4-L employed one instead of two inductions and consolidations. To compensate for potential loss of efficacy of TT4-L, bortezomib and thalidomide were added to fractionated melphalan 50 mg/m2/d for 4 days.Results: Grade ≥3 toxicities and treatment-related mortalities were not reduced in TT4-L. Complete response (CR) rates were virtually identical (P = 0.2; TT4-S, 59%; TT4-L, 61% at 2 years), although CR duration was superior with TT4-S (P = 0.05; TT4-S, 87%; TT4-L, 81% at 2 years). With a median follow-up of 4.5 years, there was no difference in overall survival (OS) and progression-free survival (PFS). Whereas metaphase cytogenetic abnormalities (CAs) tended to be an adverse feature in TT4-S, as with predecessor TT trials, the reverse applied to TT4-L. Employing historical TT3a as training and TT3b as test set, 51 gene probes (GEP51) significantly differentiated the presence and absence of CA (q < 0.0001), seven of which function in DNA replication, recombination, and repair. Applying the GEP51 model to clinical outcomes, OS and PFS were significantly inferior with GEP51/CA in TT4-S; such a difference was not observed in TT4-L.Conclusions: We identified a prognostic CA-linked GEP51 signature, the adversity of which could be overcome by potentially synergizing anti–multiple myeloma effects of melphalan and bortezomib. These exploratory findings require confirmation in a prospective randomized trial. Clin Cancer Res; 23(11); 2665–72. ©2016 AACR.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC